Inveresk Research

What Inveresk Research does

Inveresk Research, founded in 1999 and headquartered in Cary, North Carolina, was a contract research organization (CRO) providing drug development services to clients in the pharmaceutical and biotechnology industries. The firm historically operated at meaningful scale, with reported headcount in the 1,001-5,000 range, and was publicly traded on NASDAQ under the ticker symbol IRGI before being delisted. Walter S. Nimmo served as Chief Executive Officer and President.

The company's service offering centered on supporting drug development programs for pharma and biotech sponsors, though specific service lines, therapeutic area specialization, laboratory footprint, and platform architecture are not documented in the available inputs. The firm carried no firmographic detail on products, customers, partnerships, certifications, regulatory actions, M&A activity, funding rounds, or pricing, indicating either a data gap or — more consistent with other signals — an entity no longer maintaining active operations or public disclosure.

The firm's corporate domain (inveresk.com) is currently listed for resale by HugeDomains at $4,895, and the company carries no current operating status, employee count updates, or revenue disclosures. Combined with the delisted status, this pattern is consistent with a company that has wound down, been acquired without subsequent public disclosure, or otherwise exited independent operations, though no definitive dissolution, acquisition, or asset-transfer record is present in the supplied data.

Name

Inveresk Research

Website

https://inveresk.com

Company type

Private

Founded year

1999

Headcount range

1,001–5,000 employees

Short description

Inveresk Research was a Cary, North Carolina-based contract research organization founded in 1999 that provided drug development services to pharmaceutical and biotechnology clients. The firm previously traded on NASDAQ as IRGI before being delisted.

Ownership category

akta.pro rank

Product category

Drug development services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API Process Development & Route Scouting (HLAGAHAA)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Drug development services
• Pharmaceutical industry services
• Biotechnology industry services
• Pharmaceutical research
• Biotechnology research

Headquarters

HQ city

Cary

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Core offering

Provides drug development services to companies in the pharmaceutical and biotechnology industries. The offering is service-based support for drug development work rather than a named software or physical product.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug development services Service-based drug development support for pharmaceutical and biotechnology companies.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Broad incumbents

• ICON plc: Global CRO providing drug development and clinical research services to pharmaceutical and biotechnology sponsors, with broad capabilities overlapping Inveresk's offering.
• Parexel International: Global CRO providing clinical development, regulatory, and commercialization services to pharma/biotech, comparable in service breadth to Inveresk's drug development positioning.
• PPD (Thermo Fisher Scientific): Large CRO acquired by Thermo Fisher, offering full-service drug development across all phases. Direct competitor to Inveresk in the contract research and development services market.
• Charles River Laboratories: Global CRO/CDMO providing drug discovery, development, and manufacturing services across small molecules and biologics. Direct competitor in preclinical and early-stage drug development services and historically tied to Inveresk's category of work.
• IQVIA: Largest global CRO and life-sciences services platform, offering full-spectrum drug development and clinical research services. Competes with Inveresk for pharma and biotech sponsor contracts across the development lifecycle.
• Labcorp Drug Development (formerly Covance): Integrated CRO and central laboratory services provider serving pharma/biotech across preclinical and clinical development. A directly comparable peer in drug development services.

Direct peers

• Syneos Health: Biopharmaceutical services organization offering clinical development and commercialization services. Direct competitor for outsourced drug development contracts.
• Worldwide Clinical Trials: Mid-sized CRO providing drug development services to pharma/biotech, with comparable scale and service scope to Inveresk, particularly in mid-tier sponsor relationships.
• Medpace: Mid-sized CRO focused on drug development services for pharma and biotech sponsors, particularly in small and mid-sized sponsor segments. Closely aligned in service mix and customer base with Inveresk.

Emerging players

• Wuxi AppTec: Global CRO/CDMO with strong small-molecule API development, process R&D, and GMP manufacturing capabilities — directly comparable to Inveresk's small-molecule development services focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inveresk Research